2020 Life Sciences Securities Litigation Roundup | Wilson Sonsini Goodrich & Rosati
2020 Filings While there was a more than 20 percent decline in the number of securities class actions filed in 2020 (approximately 330 cases) as compared to 2019 (approximately 430 cases), the percentage of cases filed against life sciences companies remained steady at more than 20 percent of the total. 1 Only a half dozen of the new 2020 filings related to COVID-19. These statistics illustrate that life sciences companies remain attractive targets for securities class action plaintiffs. This is so for several reasons. The uncertainties facing drug and medical device companies are often binar...
Source: jdsupra.com